viewLexaria Bioscience Corp.

Full interview: Lexaria Bioscience and Cannadips CEO’s discuss key point of massive deal together

Lexaria BioScience (OTC: LXRP-CSE: LXX) CEO Chris Bunka and Case Mandel, CEO of Cannadips joined Steve Darling from Proactive Vancouver on Skype with news the company has signed a licensing deal for their DehydraTech technology with Cannadips from Humboldt, California.

Bunka telling Proactive this is a massive deal for the company that will see products in roughly 5000 stores across the U.S. Mandel talks about why they went with Lexaria and how he feels this technology makes them a leader in the space. 

Quick facts: Lexaria Bioscience Corp.

Price: 0.335 CAD

Market: CSE
Market Cap: $30.01 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...



Full interview: Lexaria Bio Science files patent for technology to treat...

Lexaria Bioscience (CSE: LXX-OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to discuss the company has filed a patent for their DehydraTech technology for the delivery of antiviral drugs. Bunka telling Proactive this technology would potentially be used to improve...

on 21/4/20

2 min read